Biology Institute, Qilu University of Technology (Shandong Academy of Sciences), Jinan 250103, China.
Engineering Research Center of Zebrafish Models for Human Diseases and Drug Screening of Shandong Province, Jinan 250103, China.
Mar Drugs. 2024 Sep 26;22(10):439. doi: 10.3390/md22100439.
Existing antithrombotic drugs have side effects such as bleeding, and there is an urgent need to discover antithrombotic drugs with better efficacy and fewer side effects. In this study, a zebrafish thrombosis model was used to evaluate the antithrombotic activity and mechanism of Brevianamide F, a deep-sea natural product, with transcriptome sequencing analysis, RT-qPCR analysis, and molecular docking. The results revealed that Brevianamide F significantly attenuated the degree of platelet aggregation in the thrombus model zebrafish, leading to an increase in the number of circulating platelets, an augmentation in the return of blood to the heart, an elevated heart rate, and a significant restoration of caudal blood flow velocity. Transcriptome sequencing and RT-qPCR validation revealed that Brevianamide F may exert antithrombotic effects through the modulation of the MAPK signaling pathway and the coagulation cascade reaction. Molecular docking analysis further confirmed this result. This study provides a reference for the development of therapeutic drugs for thrombosis.
现有的抗血栓药物具有出血等副作用,因此急需发现疗效更好、副作用更少的抗血栓药物。本研究采用斑马鱼血栓模型,通过转录组测序分析、RT-qPCR 分析和分子对接,评估深海天然产物 Brevianamide F 的抗血栓活性和机制。结果表明,Brevianamide F 可显著减轻血栓模型斑马鱼的血小板聚集程度,导致循环血小板数量增加、血液回流心脏增加、心率升高、尾部血流速度显著恢复。转录组测序和 RT-qPCR 验证表明,Brevianamide F 可能通过调节 MAPK 信号通路和凝血级联反应发挥抗血栓作用。分子对接分析进一步证实了这一结果。本研究为血栓治疗药物的开发提供了参考。